Companies ›Healthcare ›MX1.AX

MX1.AX — ASX Advanced Medical Equipment & Technology

Micro-X Ltd

A$0,04

Open in Charts → Attach watcher ⌖

— —

AUD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Micro-X Ltd develops and commercializes portable X-ray imaging systems for point-of-care diagnostics, primarily targeting the healthcare sector.

Business. Micro-X Ltd (MX1.AX) is an advanced medical equipment and technology company operating within the healthcare services and equipment sector. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. As specific segment and geographic data are not provided, the company is described at the industry level as a provider of advanced medical technology products.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

Generated · model-assisted

Sell-side consensus

BUY1 analysts

1 buy0 hold0 sell

Avg 12m price target0,15

Analyst recommendations

1 analysts · consensus Buy

Buy1

Hold0

Sell0

12-month price target

0,15

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

1 analysts · indicative

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning MX1.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to MX1.AX. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Micro-X Ltd (MX1.AX) is an advanced medical equipment and technology company operating within the healthcare services and equipment sector. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. As specific segment and geographic data are not provided, the company is described at the industry level as a provider of advanced medical technology products.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

AI synthesis

GENERATED

— missing data

Key takeaways

Micro-X operates in the Advanced Medical Equipment & Technology industry with a fully diluted share count of 729,189,469.
Analysts have assigned a strong buy rating with a mean price target of 0.15 AUD.
No liquidity metrics or profitability data are available for benchmarking.
Revenue concentration and geographic exposure are not disclosed.
No forward-looking guidance or growth trajectory is available in the current dataset.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Annual

ANNUALFiled 2025-08-28

FY 2025 · Full-year highlights

Revenue A$13.1M, −14,2% YoY; Operating income −16,4% YoY.

RevenueA$13.1M−14,2 % YoY

Operating income-A$18.9M−16,4 % YoY

Net income-A$13.9M−42,3 % YoY

Free cash flow-A$12.4M−44,9 % YoY

EPS—

Operating cash flow-A$8.6M−33,5 % YoY

Financials

Income statement

RevenueA$13.1M

Gross profitA$10.3M

Operating income-A$18.9M

Net income-A$13.9M

Margins

Gross margin79.1%

Operating margin-145.0%

Net margin-106.5%

FCF margin-95.3%

Balance sheet

Total assetsA$22.1M

Total liabilitiesA$14.6M

Total equityA$7.5M

Cash & equivalentsA$3.2M

Long-term debtA$6.5M

Cash flow

Operating cash flow-A$8.6M

CapEx-A$100.0k

Free cash flow-A$12.4M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue A$13.1M, −14,2% YoY
▍Operating income −16,4% YoY
▍Net income −42,3% YoY
▍Free cash flow −44,9% YoY
▍Net margin -106.5%

Valuation FY

Market price

A$0,04

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,01

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-08 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,01
Revenue	—no estimate	—no estimate	26,9M AUD
Operating income	—no estimate	—no estimate	-6,8M AUD

Full-year consensus mean (period as reported by source) · consensus in AUD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy1

Buy0

Hold0

Sell0

Strong sell0

12-month price targetA$0,15 · Median A$0,15

Low A$0,15High A$0,15

Operating income · consensus-6,8M AUD

EPS surprise

−150,0 %

reported vs consensus · miss

Revenue surprise

−30,7 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

LowA$0,15

MeanA$0,15

MedianA$0,15

HighA$0,15

SpotA$0,04

+328.6 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic

Source documents

Micro-X Ltd Market data — financials · 2026-05-28
Micro-X Ltd Market data — analyst estimates · 2026-05-28

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

MX1.AXCanonical

ASX · AUD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2025-08-28 04:32 UTCEARNINGSAnnual results — FY 2025 Revenue AUD 13.1M · Net AUD -13.9M

2024-08-29 04:09 UTCEARNINGSAnnual results — FY 2024 Revenue AUD 15.2M · Net AUD -9.8M

2023-08-30 04:37 UTCEARNINGSAnnual results — FY 2023 Revenue AUD 15.0M · Net AUD -10.8M

2022-08-30 05:28 UTCEARNINGSAnnual results — FY 2022 Revenue AUD 13.1M · Net AUD -17.1M

2021-08-27 03:50 UTCEARNINGSAnnual results — FY 2021 Revenue AUD 6.8M · Net AUD -14.7M

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread